Scar News and Research

RSS

Nanocomposite brain probe induces less scarring after implantation

A hard probe inserted in the cerebral cortex of a rat model turns nearly as pliable as the surrounding gray matter in minutes, and induces less of the tough scarring that walls off hard probes that do not change, researchers at Case Western Reserve University have found.

4 Nov 2011

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.

3 Nov 2011

Lucile Packard Children’s Hospital surgeons successfully separate conjoined twins

Formerly conjoined twins Angelica and Angelina Sabuco have been successfully separated, physicians at Lucile Packard Children's Hospital announced late this afternoon.

2 Nov 2011

Neutralization approach appears to prevent proliferative vitreoretinopathy

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.

31 Oct 2011

Blood biomarker panel can predict survival in IPF patients

A panel of blood proteins can predict which patients with the progressive lung disease idiopathic pulmonary fibrosis (IPF) are likely to live at least five years or to die within two years, say researchers at the University of Pittsburgh School of Medicine and Centocor R&D.

27 Oct 2011

Study evaluates pain associated with surgical incisions/scars before repeat cesarean procedures

A study presented at ANESTHESIOLOGY 2011 in Chicago is perhaps the first to evaluate pain associated with surgical incisions or scars before repeat cesarean (CS) procedures, and the data could lead to improved care for a rapidly growing and unique group of patients.

18 Oct 2011

UEI tool could allow doctors to deliver efficient, timely treatment for Crohn's disease

It's difficult for doctors to tell whether a patient with Crohn's disease has intestinal fibrosis, which requires surgery, or inflammation, which can be treated with medicine. A new imaging method might make that task easier, according to a U-M-led study.

15 Oct 2011

Potential vaccine against trachoma

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

10 Oct 2011

Brave breast cancer survivors on camera – scars and all

David Jay is a fashion photographer who has spent years capturing images of perfectly formed beautiful women. About five years ago, he began shooting young breast cancer survivors after his girlfriend's twin sister was diagnosed with the disease in her late 20s. His motive was to raise awareness that breast cancer can ravage young women as well as old.

3 Oct 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

23 Sep 2011

NIH-funded project to develop new class of tissue regeneration therapeutics

The National Institutes of Health (NIH) has awarded nearly $2 million to researchers at the Georgia Institute of Technology and Emory University to develop a new class of therapeutics for treating traumatic injuries and degenerative diseases.

22 Sep 2011

St. Jude Medical to again participate in Asia-Pacific Heart Rhythm Society Scientific Session

St. Jude Medical, Inc., a global medical device company, is pleased to again participate in the Asia-Pacific Heart Rhythm Society Scientific Session (APHRS), which is being held this year in conjunction with the Japanese Heart Rhythm Society (JHRS) and the Japanese Society of Electrocardiology (JSE) in Fukuoka, Japan.

16 Sep 2011

Smith & Nephew launches DYONICS PLATINUM Series Shaver Blades for arthroscopy procedures

Smith & Nephew today announced the launch of its innovative, single-use DYONICS PLATINUM Series Shaver Blades which deliver superior arthroscopic resection, debris evacuation and sharpness.

8 Sep 2011

Exercise, intervention may help individuals with peripheral arterial disease

Peripheral arterial disease, or PAD, is a common condition affecting 12-20 percent of Americans age 65 and older that may be a signal of future heart attack and stroke-and many with the disease may be unaware they have it, says the Society of Interventional Radiology.

8 Sep 2011

St. Jude Medical receives approval for CRT-D quadripolar pacing system in India

St. Jude Medical, Inc., a global medical device company, today announced the approval of the industry's first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds) in India. The Promote Quadra CRT-D offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

7 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Loyola surgeons use new, less invasive catheter technique to treat cystic fibrosis

Cystic fibrosis patient Daniel Sammons had undergone a successful double lung transplant at Loyola University Medical Center, but he still had one major health issue.

3 Sep 2011

Victims of intimate partner violence more likely to develop mental health disorders

Victims who suffer violence at the hands of a spouse, boyfriend or girlfriend, or other intimate partner aren't only brutalized physically; they also suffer disproportionately higher rates of mental health distress, according to a new policy brief from the UCLA Center for Health Policy Research.

31 Aug 2011